FDA authorizes Virtuoso's needle-armed robot for removing bladder tumors in one piece

Virtuoso Surgical said on Nov. 10, 2026, that the U.S. FDA granted De Novo authorization for the Virtuoso Endoscopy System, a Breakthrough-designated surgical robot for en bloc resection of bladder lesions in adults, making it the first device in a new FDA classification for electromechanical endoluminal surgical systems.

Bladder tumor surgery has mostly meant shaving tumors out in pieces with tools that haven't changed much in a century — and then asking pathologists to stage the cancer from the confetti. Virtuoso's bet is that two tiny robot arms can lift and cut so the tumor comes out whole. The FDA just created a whole new device category to let it try. Twenty patients at one site is a promising start, not a verdict; the 2027 U.S. rollout is where the real numbers show up.

Virtuoso Surgical said the U.S. Food and Drug Administration granted De Novo authorization for the Virtuoso Endoscopy System. De Novo is the path the FDA uses when a device is new enough that nothing already sold can be the comparison. The agency put it in a new class, "electromechanical surgical systems for endoluminal surgical procedures." Endoluminal means the instruments go through an endoscope, a tube with a camera, into a hollow part of the body. Virtuoso says this is the first device in that class. The company newsroom dates the grant to Oct. 30, 2026. The public announcement is Nov. 10, 2026. Those lines are Virtuoso's.

The authorization covers en bloc resection of bladder lesions in adults. En bloc means the lesion comes out in one piece, or in larger segments, instead of in scraps. The job is to obtain tissue, including detrusor muscle, the muscle in the bladder wall, to help a doctor evaluate bladder cancer. The approach is transurethral: the tools go in through the urethra, the tube that empties the bladder, with no cut in the skin. Trained surgeons use it in an operating room. The announcement does not give a price, and it does not give a De Novo number. Those limits are the company's.

The FDA named the system a Breakthrough Device in September 2025. Breakthrough designation is a program that can move a review faster when a device is aimed at a serious condition. It is not the same thing as the authorization that just landed. That date is Virtuoso's.

The working end is two needle-sized robotic arms, made of superelastic concentric nitinol tubes, at the tip of a standard-sized rigid endoscope. Nitinol is a nickel-titanium metal that bends and springs back. Concentric means the tubes sit inside one another so the arm can curve. A surgeon sits at a console, and the arms follow the surgeon's hand motions. One arm lifts and retracts tissue. The other dissects underneath. That is two-handed work through the urethra, which a single straight tool cannot do. The system is a tool a surgeon drives. The announcement does not describe it choosing a cut on its own. Those lines are the company's.

The usual operation is TURBT, transurethral resection of a bladder tumor. Surgeons typically shave the tumor out in fragments. En bloc resection is meant to keep the tissue together so a pathologist can stage the cancer, which means judging how deep it has grown. The American Cancer Society estimates about 84,530 Americans will be newly diagnosed with bladder cancer in 2026. Virtuoso cites that figure. It is the society's estimate, not a result from this device.

The company points to the VIABLE study, registered as NCT06940648. The first 20 patients were all treated at The Chinese University of Hong Kong. Detrusor muscle was present in 94% of the removed lesions. The study's performance goal was 60%. Virtuoso says a review of published conventional TURBT studies puts the median around 70%. Margins were evaluable in 93% of malignant lesions, meaning a pathologist could read the edge of the cancer. The company reports no intraoperative adverse events, harm that shows up during the operation itself. Twenty patients at one hospital is a start. It is not a multi-hospital verdict. Those numbers are Virtuoso's, and the company labels them preliminary.

Duke Herrell, M.D., is chief executive and a urologic surgeon. He is quoted in the announcement. Sam S. Chang, M.D., of the Vanderbilt-Ingram Cancer Center, is quoted too. Virtuoso says he is a paid adviser and consultant and holds stock options. Professor Jeremy Teoh of The Chinese University of Hong Kong, the principal investigator on VIABLE, is also quoted. Those roles are in the release.

A focused U.S. launch at leading urology centers is planned for 2027. Uses in gynecology, pulmonary medicine, and neurosurgery are investigational only, which means they are still research and are not part of this authorization. Virtuoso was founded in 2016 in Nashville. The technology came from Vanderbilt University, Johns Hopkins, and Vanderbilt University Medical Center, with support from the National Science Foundation and the National Institutes of Health. Those lines are the company's.

The picture is the Virtuoso Endoscopy System: a surgeon console with two hand controls, beside the robot cart, and a suspended arm holding the rigid endoscope with its motor pack. The credit is Virtuoso Surgical.

In plain terms, the FDA created a new device category and authorized a Nashville robot that puts two needle-sized arms through a rigid scope, so a surgeon can lift and cut a bladder lesion out in one piece. The early study is 20 patients at one site. A U.S. launch at selected urology centers is planned for 2027. It is a tool for taking tissue so doctors can stage bladder cancer. It is not a claim that the cancer is cured.